Friday, September 30, 2016 4:05:17 PM
After Threshold announced negative interim results with tarloxotinib, a hypoxia induced irreversible (covalent) epidermal growth factor receptor (EGRF) inhibitor, in two Phase II trials, shares are subsequently plunging nearly 56%. Because tarloxotinib failed to meet prespecified efficacy thresholds, all future development on the pipeline drug has been halted.
Additionally, the biotech firm announced to retain capital, its workforce will be reduced, instead opting to shift focus to regulatory discussions in Japan for its pipeline pancreatic cancer drug evofosfamide.
Despite the adverse results for tarloxotinib and THLD reduction in workforce, William Blair analyst John Sonnier reiterates an Outperform rating on shares of THLD without listing a price target.
Sonnier explains, “We believe the potential regulatory path forward with evofosfamide in pancreatic cancer in Japan could transform the company’s valuation and P&L statement. With $33.6 million in cash at the end of the second quarter, we believe the capital should be sufficient to bridge the company to the next material inflection point.”
Furthermore, the analyst understands the biotech firm’s choice to terminate the development on the pipeline drug, asserting, “We agree with management’s decision to discontinue development of tarloxotinib due to the lack of a clear efficacy signal from the Phase II programs.”
In THLD’s favor, Sonnier sees promise as the firm pursues Investigational New Drug-enabling studies with TH-3424, a novel AKR1C3 activated prodrug designed to treat cancer. The drug has already indicated to be considerably upregulated in particular kinds of tumors, including hepatocellular carcinoma.
“Preclinical data supports the ability of TH-3424 to effectively kill cancer cells with upregulated AKR1C3, and we look forward to future updates with the compound,” the analyst concludes.
http://www.smarteranalyst.com/2016/09/30/william-blair-weighs-threshold-pharmaceuticals-inc/
Recent MTEM News
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement • GlobeNewswire Inc. • 03/28/2024 12:11:00 PM
- Molecular Templates, Inc. Provides Interim Update • GlobeNewswire Inc. • 03/04/2024 01:11:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:39:50 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:45:31 PM
- Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/08/2024 10:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:49:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:34:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:32:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:04:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:13:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:12:59 PM
- Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/13/2023 09:11:00 PM
- Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors • GlobeNewswire Inc. • 11/02/2023 08:11:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 08:14:59 PM
- Molecular Templates to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/01/2023 08:12:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:46:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:45:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:45:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:12:14 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 09:08:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 09:01:30 PM
- Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer • GlobeNewswire Inc. • 09/28/2023 08:11:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM